|
Market Closed -
Nasdaq
16:00:00 2026-10-16 EDT
|
5-day change | 1st Jan Change | ||
| 1.100 USD | -2.65% |
|
-8.33% | -52.79% |
| 08-12 | Spero Therapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026 | |
| 08-12 | Spero Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: Spero Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 517.5 | 89.57 | 77.91 | 56.15 | 131.3 | 64.06 | - |
| Change | - | -82.69% | -13.02% | -27.92% | 133.77% | -51.2% | - |
| Enterprise Value (EV) | 371.1 | 89.57 | 77.91 | 56.15 | 131.3 | 64.06 | 64.06 |
| Change | - | -75.86% | -13.02% | -27.92% | 133.77% | -51.2% | 0% |
| P/E | -5.5x | -1.41x | 3.42x | -0.81x | 15.5x | -1.9x | -10.5x |
| PBR | - | - | - | - | - | - | - |
| PEG | - | 0x | -0x | 0x | -0x | 0x | 0.1x |
| Capitalization / Revenue | 28.3x | 1.67x | 0.75x | 1.17x | - | 248x | - |
| EV / Revenue | 0x | 0x | 0x | 0x | - | 248x | - |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | 0x | -0x | - | -1.75x | -1.16x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -2.91 | -1.23 | 0.43 | -1.27 | 0.15 | -0.58 | -0.105 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 18.26 | 53.51 | 103.8 | 47.98 | - | 0.258 | - |
| EBITDA | -87.32 | - | - | - | - | - | - |
| EBIT 1 | -87.97 | -42.2 | 21.48 | -73.36 | - | -36.66 | -55 |
| Net income 1 | -89.76 | -46.42 | 22.81 | -68.57 | - | -33.46 | -51.5 |
| Net Debt | -146.4 | - | - | - | - | - | - |
| Reference price 2 | 16.010 | 1.730 | 1.470 | 1.030 | 2.330 | 1.100 | 1.100 |
| Nbr of stocks (in thousands) | 32,324 | 51,776 | 52,999 | 54,518 | 56,339 | 58,235 | - |
| Announcement Date | 3/31/22 | 3/30/23 | 3/13/24 | 3/27/25 | 3/26/26 | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.9x | - | - | - | 64.06M | |
| 18.77x | 6.69x | 13.41x | 1.58% | 65B | |
| 35.3x | 6.27x | 18.74x | 0.92% | 51.2B | |
| 27.56x | 7.53x | 23.83x | 0.05% | 51.19B | |
| 34.01x | 3.32x | 14.33x | -.--% | 43.93B | |
| 48.9x | 5.59x | 30.73x | -.--% | 41.96B | |
| -18.47x | 189.62x | -19.51x | -.--% | 38.14B | |
| 28.97x | 8.21x | 21.25x | 0.37% | 33.24B | |
| 29.19x | 6.17x | 16.01x | -.--% | 25.2B | |
| 30.74x | 5.69x | 19.09x | -.--% | 22.5B | |
| Average | 23.31x | 26.57x | 15.32x | 0.32% | 37.24B | |
| Weighted average by Cap. | 25.96x | 25.01x | 15.48x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SPRO Stock
- Valuation Spero Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
